-
公开(公告)号：US20070237741A1
公开(公告)日：2007-10-11
申请号：US11732909
申请日：2007-04-05
Applicant: Garret D. Figuly , Surbhi Mahajan , Rinaldo S. Schiffino , Sujata K. Bhatia , Elazer R. Edelman , Tarek Michael Shazly , Michael Jordan Feldstein
Inventor： Garret D. Figuly , Surbhi Mahajan , Rinaldo S. Schiffino , Sujata K. Bhatia , Elazer R. Edelman , Tarek Michael Shazly , Michael Jordan Feldstein
IPC: A61K8/72 , C08J9/32 , A61K9/00 , A61K31/785
CPC classification number: A61K9/16 , A61K9/1635 , A61K9/1652 , A61K9/1682 , A61K31/785 , A61L15/24 , A61L15/44
Abstract: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications.
Abstract translation: 开发了一种治疗方法，其中在哺乳动物中施用具有新特性的微球。 使用新颖的方法制备微球，其导致具有高密度，低断裂，高溶胀能力，膨胀膨胀和膨胀后的变形性的新组合性质的微球。 这些微球可以用于空隙填充，组织膨胀，非脉管闭塞，体液吸收和药物的递送。
-
公开(公告)号：US08252339B2
公开(公告)日：2012-08-28
申请号：US11732909
申请日：2007-04-05
Applicant: Garret D. Figuly , Surbhi Mahajan , Rinaldo S. Schiffino , Sujata K. Bhatia , Elazer R. Edelman , Tarek Michael Shazly , Michael Jordan Feldstein
Inventor： Garret D. Figuly , Surbhi Mahajan , Rinaldo S. Schiffino , Sujata K. Bhatia , Elazer R. Edelman , Tarek Michael Shazly , Michael Jordan Feldstein
CPC classification number: A61K9/16 , A61K9/1635 , A61K9/1652 , A61K9/1682 , A61K31/785 , A61L15/24 , A61L15/44
Abstract: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications.
Abstract translation: 开发了一种治疗方法，其中在哺乳动物中施用具有新特性的微球。 使用新颖的方法制备微球，其导致具有高密度，低断裂，高溶胀能力，膨胀膨胀和膨胀后的变形性的新组合性质的微球。 这些微球可以用于空隙填充，组织膨胀，非脉管闭塞，体液吸收和药物的递送。
-
公开(公告)号：US07842083B2
公开(公告)日：2010-11-30
申请号：US11363123
申请日：2006-02-27
Applicant: John F. Shanley , Neal L. Eigler , Elazer R. Edelman
Inventor： John F. Shanley , Neal L. Eigler , Elazer R. Edelman
CPC classification number: A61F2/915 , A61F2/91 , A61F2002/91533 , A61F2002/91558 , A61F2250/0004 , A61F2250/0068
Abstract: An expandable medical device having a plurality of elongated struts, the plurality of elongated struts being joined together by ductile hinges to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. The plurality of struts and ductile hinges are arranged to improve the spatial distribution of the struts which is particularly important when delivering beneficial agents with the struts. The improved strut arrangement expands to a substantially parallelogram shape for improved beneficial agent distribution to the surrounding tissue. A beneficial agent may be loaded into openings within the struts or coated onto the struts for delivery to the tissue.
Abstract translation: 一种具有多个细长支柱的可扩张医疗装置，所述多个细长支柱通过延性铰链连接在一起以形成可从具有第一直径的圆柱体膨胀至具有第二直径的圆柱体的基本上圆柱形的装置。 多个支柱和延性铰链被布置成改善支柱的空间分布，这在用支柱输送有益试剂时是特别重要的。 改进的支柱布置扩展到基本上平行四边形的形状，以改善对周围组织的有益剂分布。 有益剂可以装载到支柱内的开口中或涂覆到支柱上以输送到组织。
-
公开(公告)号：US07208010B2
公开(公告)日：2007-04-24
申请号：US09948989
申请日：2001-09-07
Applicant: John F. Shanley , Neal L. Eigler , Kinam Park , Elazer R. Edelman
Inventor： John F. Shanley , Neal L. Eigler , Kinam Park , Elazer R. Edelman
IPC: A61F2/06
CPC classification number: A61L31/10 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2002/91558 , A61F2210/0004 , A61F2210/0076 , A61F2250/003 , A61F2250/0031 , A61F2250/0068 , A61L31/148 , A61L31/16 , A61L2300/416 , A61L2300/42 , A61L2300/602 , A61L2300/622
Abstract: An expandable medical device has a plurality of elongated struts joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. At least one of the plurality of struts includes at least one opening extending at least partially through a thickness of the strut. A beneficial agent is loaded into the opening within the strut in layers to achieve desired temporal release kinetics of the agent. Alternatively, the beneficial agent is loaded in a shape which is configured to achieve the desired agent delivery profile. A wide variety of delivery profiles can be achieved including zero order, pulsatile, increasing, decrease, sinusoidal, and other delivery profiles.
Abstract translation: 可扩张医疗装置具有连接在一起的多个细长支柱，以形成一个基本上圆柱形的装置，该装置可从具有第一直径的圆柱体扩展到具有第二直径的圆筒。 所述多个支柱中的至少一个支柱包括至少部分穿过支柱的厚度延伸的至少一个开口。 将有益剂加载到支柱内的开口中以实现试剂的期望的释放动力学。 或者，有益试剂被加载成被配置成实现所需试剂输送曲线的形状。 可以实现各种各样的输送曲线，包括零级，脉冲，增加，减少，正弦和其他输送曲线。
-
25.发明授权公开(公告)号：US07066905B2
公开(公告)日：2006-06-27
申请号：US10293002
申请日：2002-11-13
Applicant: James C. Squire , Elazer R. Edelman , Paul Tierstein
Inventor： James C. Squire , Elazer R. Edelman , Paul Tierstein
CPC classification number: A61M25/1011 , A61M25/01 , A61M2025/1086
Abstract: Embodiments of the present invention are directed to a method and apparatus for accurate positioning of a dual balloon catheter. In one embodiment of the present invention, a first balloon provides an anchoring point. In one embodiment, the first balloon has protrusions to help secure its position. In one embodiment, once the first balloon is inflated, it provides a fixed position relative to which a second balloon is accurately positioned in the treatment region. In another embodiment, a second balloon imparts a radial force. In another embodiment, a second balloon imparts an axial force, using the first balloon as an anchor against which the force is applied. The force may be applied in a forward or a backward direction. In yet another embodiment, a second balloon imparts a rotational force, using the first balloon as an anchor against which the force is applied.
Abstract translation: 本发明的实施例涉及一种用于双球囊导管的精确定位的方法和装置。 在本发明的一个实施例中，第一球囊提供锚定点。 在一个实施例中，第一气囊具有突起以帮助确保其位置。 在一个实施例中，一旦第一球囊被充气，其提供固定位置，相对于该固定位置，第二球囊被准确地定位在治疗区域中。 在另一个实施例中，第二球囊赋予径向力。 在另一个实施例中，第二球囊使用第一气球作为施加力的锚杆施加轴向力。 该力可以向前或向后施加。 在另一个实施例中，第二球囊使用第一气球作为施加力的锚杆施加旋转力。
-
Patent Agency Ranking
公开(公告)号：US10517883B2
公开(公告)日：2019-12-31
申请号：US10607623
申请日：2003-06-27
Applicant: Haim D. Danenberg , Gershon Golomb , Elazer R. Edelman
Inventor： Haim D. Danenberg , Gershon Golomb , Elazer R. Edelman
IPC: A61K31/663 , A61K9/127 , A61K9/51 , A61K31/66 , A61K31/675
Abstract: A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intra-cellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages. The formulation may comprise an encapsulated agent, an embedded agent or a particulate agent, wherein the formulation is of a specific size, such that it can enter cells primarily via phagocytosis. The formulation is preferably in the size range of 0.03-1.0 microns.
-
公开(公告)号：US09480404B2
公开(公告)日：2016-11-01
申请号：US12578365
申请日：2009-10-13
Applicant: Natalie Artzi , Elazer R. Edelman
Inventor： Natalie Artzi , Elazer R. Edelman
CPC classification number: A61B5/0059 , G06F19/00 , G06F19/321 , G06T7/0012
Abstract: A method for imaging the erosion of a biomaterial is disclosed. More specifically, the present invention provides a method for imaging a labeled biomaterial so that the erosion of the biomaterial is measured in vivo over a period of time. A biomaterial such as, for example, a hydrogel including polyethylene glycol (PEG) is labeled with a fluorescent or bioluminescent marker. The labeled biomaterial is then employed in the construction of an implanted medical device such as, for example, an endovascular stent. Furthermore, the labeled biomaterial may be utilized to form a drug delivery system that releases a controlled amount of a drug into a local region within a patient. The erosion of the biomaterial is monitored through a noninvasive imaging method.
Abstract translation: 公开了一种用于对生物材料侵蚀进行成像的方法。 更具体地，本发明提供了一种用于对标记的生物材料进行成像的方法，使得在一段时间内在体内测量生物材料的侵蚀。 诸如例如包括聚乙二醇（PEG）的水凝胶的生物材料用荧光或生物发光标记物标记。 然后将标记的生物材料用于构建植入的医疗装置，例如血管内支架。 此外，标记的生物材料可以用于形成将受控量的药物释放到患者内的局部区域中的药物递送系统。 通过非侵入性成像方法监测生物材料的侵蚀。
-
28.发明申请Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity 审中-公开用于生长因子稳定性和活性的受体和/或共受体的同时递送公开(公告)号：US20140066374A1
公开(公告)日：2014-03-06
申请号：US13887722
申请日：2013-05-06
Applicant: Elazer R. Edelman , Aaron B. Baker
Inventor： Elazer R. Edelman , Aaron B. Baker
CPC classification number: A61K38/1825 , A61K38/177 , A61K38/179 , A61K38/1793 , A61K38/1841 , A61K38/39 , A61K38/47 , A61K47/6911 , A61K2300/00
Abstract: The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors and co-receptors, such as syndecans. Co-delivery of growth factors with syndecans, for example, may protect growth factors from proteolysis, enhance their activity, and target the growth factors to the cell surface to facilitate growth factor signaling. This novel approach to growth factor therapy could be extended to other systems and growth factors enabling the enhancement of multiple signaling pathways to achieve a desired therapeutic outcome.
Abstract translation: 本发明的组合物和方法涉及将分子和多肽共同递送至细胞以改善分子的治疗功效。 在本发明的一个实施方案中，本发明可以通过将这些生长因子与其受体和共受体（例如syndecans）共同递送来改善生长因子的递送。 例如，与综合征共同递送生长因子可以保护生长因子免于蛋白水解，增强其活性，并将生长因子靶向细胞表面以促进生长因子信号传导。 这种生长因子治疗的新方法可以扩展到其他系统和生长因子，从而能够增强多个信号传导途径以实现期望的治疗结果。
-
29.发明申请Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs 审中-公开改变对包含同基因和非同基因细胞，组织或器官的外源和内源性免疫原的免疫应答的材料和方法公开(公告)号：US20130177600A1
公开(公告)日：2013-07-11
申请号：US13570320
申请日：2012-08-09
Applicant: Elazer R. Edelman , Helen Marie Nugent , Heiko Methe
Inventor： Elazer R. Edelman , Helen Marie Nugent , Heiko Methe
CPC classification number: A61K35/44 , A61K9/00 , A61K39/001 , A61K45/06 , A61K2035/122 , C12N5/069 , C12N2533/54
Abstract: Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.
Abstract translation: 本文公开了调节对外源或内源性免疫原（包括细胞，组织或器官相关免疫原）的免疫学不良反应的材料和方法。 锚定或嵌入在生物相容性基质中的包含细胞，例如但不限于内皮细胞的可植入材料可以调节对外源或内源性免疫原的不良免疫或炎性反应，包括对非同基因或同基因细胞，组织或器官的反应， 外源性免疫原或刺激物，以及改善自身免疫病症。 可植入材料可以在发生免疫应答或炎性反应之前，同时或之后提供。 可移植材料可以诱导移植患者的免疫接受，减少移植排斥反应并降低供体抗原免疫原性。
-
30.发明申请Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair 审中-公开组织工程内皮和上皮植入物差异性和协同调节组织修复公开(公告)号：US20130064800A1
公开(公告)日：2013-03-14
申请号：US13571494
申请日：2012-08-10
Applicant: Elazer R. Edelman , Brett G. Zani
Inventor： Elazer R. Edelman , Brett G. Zani
CPC classification number: A61K35/36 , A61K35/12 , A61K35/42 , A61L27/3808 , C12N5/0688 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/25 , C12N2501/385 , C12N2501/39 , C12N2501/395 , C12N2501/81 , C12N2502/28 , C12N2533/00 , C12N2533/54
Abstract: Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.
Abstract translation: 内皮植入物在损伤后恢复血管稳态，而不会重建血管结构。 内皮细胞对血管上皮细胞和下面的vasa血管排除细胞对照之间的区别。 与血管不同，气道上皮与血管内皮细胞高度分化，区别于支气管血管，允许调查差异对照组织工程细胞可能在气道和血管中提供。 通过气道损伤和细胞培养模型，发现支气管上皮和内皮的组织工程植入物通过气道微环境的生物化学调节促进气道的协同修复。 虽然上皮细胞调节局部组织组成和反应，内皮细胞保留上皮细胞; 一起，他们的相对影响被增强，表明两种细胞类型协同作用用于气道修复。
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.019 seconds)
